康芝药业(300086) - 2025 Q2 - 季度财报

Section I Important Notes, Table of Contents, and Definitions This section provides crucial disclaimers, lists reference documents, and defines key terms used throughout the report for clarity Important Notes The company's board, supervisory board, and senior management guarantee the report's accuracy, while financial officers confirm the financial statements' integrity, with no major risks or dividend plans - The company's board, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, and bear legal responsibility[4] - The company's responsible person Hong Jiangyou, chief financial officer Li Jing, and head of accounting department Li Jing declare that the financial report in this semi-annual report is true, accurate, and complete[4] - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[5] List of Reference Documents This section lists the company's semi-annual report reference documents, including original financial reports and public disclosures, available at the company's securities department - Reference documents include the original financial report text signed and sealed by the legal representative, chief financial officer, and head of the accounting department[9] - Reference documents also include the original 2025 semi-annual report text signed by the legal representative[10] - All reference documents are available at the company's securities department[13] Definitions This section defines common terms used in the report, covering company names, institutions, regulations, subsidiaries, reporting periods, and industry-specific terminology - "Honz Pharmaceutical" refers to Honz Pharmaceutical Co., Ltd[15] - "Reporting Period" refers to the first half of 2025[15] - "OTC" refers to over-the-counter drugs, which consumers can self-diagnose and use without a doctor's prescription, being safe and effective[15] Section II Company Profile and Key Financial Indicators This section provides an overview of the company's basic information, contact details, and key financial performance metrics for the reporting period I. Company Profile Honz Pharmaceutical Co., Ltd., stock code 300086, is listed on the Shenzhen Stock Exchange, with Hong Jiangyou as its legal representative Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Honz Pharmaceutical | | Stock Code | 300086 | | Listed Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Honz Pharmaceutical Co., Ltd. | | Legal Representative | Hong Jiangyou | II. Contact Person and Information The company's board secretary is Lin Dexin, and the securities affairs representative is Lu Fangmei, with contact details remaining unchanged during the reporting period Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Lin Dexin | No. 6 Yaogu Third Road, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone | 0898-66812876 | 0898-66812876 | honz168@honz.com.cn | | Securities Affairs Representative | Lu Fangmei | No. 6 Yaogu Third Road, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone | 0898-66812876 | 0898-66812876 | honz168@honz.com.cn | III. Other Information The company's registered address, office address, website, email, information disclosure, and registration changes remained consistent with the 2024 annual report - The company's registered address, office address, website, and email remained unchanged during the reporting period, as detailed in the 2024 annual report[19] - Information disclosure and storage locations remained unchanged during the reporting period, as detailed in the 2024 annual report[20] - The company's registration status remained unchanged during the reporting period, as detailed in the 2024 annual report[21] IV. Key Accounting Data and Financial Indicators During the reporting period, the company's operating revenue increased by 5.56%, net profit attributable to shareholders narrowed losses by 46.38%, and net cash flow from operating activities surged by 4473.93% Key Accounting Data and Financial Indicators | Indicator | Current Reporting Period (yuan) | Prior Year Period (yuan) | % Change from Prior Year Period | | :--- | :--- | :--- | :--- | | Operating Revenue | 232,448,515.10 | 220,198,812.69 | 5.56% | | Net Profit Attributable to Shareholders of Listed Company | -54,081,719.36 | -100,863,188.44 | 46.38% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses | -56,007,110.23 | -105,036,622.12 | 46.68% | | Net Cash Flow from Operating Activities | 66,352,495.76 | -1,516,998.04 | 4,473.93% | | Basic Earnings Per Share (yuan/share) | -0.1188 | -0.2241 | 46.99% | | Diluted Earnings Per Share (yuan/share) | -0.1188 | -0.2241 | 46.99% | | Weighted Average Return on Net Assets | -4.86% | -7.79% | 2.93% | | Indicator | End of Current Reporting Period (yuan) | End of Prior Year (yuan) | % Change from End of Prior Year | | :--- | :--- | :--- | :--- | | Total Assets | 1,904,813,492.17 | 1,975,850,549.69 | -3.60% | | Net Assets Attributable to Shareholders of Listed Company | 1,085,827,134.57 | 1,139,922,413.01 | -4.75% | V. Differences in Accounting Data Under Domestic and International Accounting Standards The company reported no differences in net profit and net assets between financial statements prepared under international/overseas accounting standards and Chinese accounting standards - The company reported no differences in net profit and net assets between financial statements prepared under international accounting standards and Chinese accounting standards during the reporting period[23] - The company reported no differences in net profit and net assets between financial statements prepared under overseas accounting standards and Chinese accounting standards during the reporting period[24] VI. Non-Recurring Gains and Losses and Amounts Non-recurring gains and losses totaled 1,925,390.87 yuan, primarily from non-current asset disposals, government grants, and other non-operating income/expenses, while certain recurring government subsidies were excluded Non-Recurring Gains and Losses and Amounts | Item | Amount (yuan) | Explanation | | :--- | :--- | :--- | | Disposal gains/losses of non-current assets (including the reversal of impairment provisions already made) | 448,388.77 | | | Government grants recognized in current profit or loss (excluding those closely related